Volume rose sixfold on the previous seven hours as the congress opened, but about half of it is device-company messaging: an Abbott statement on CGM access syndicated 159 times across Italian regional press, and Tandem and Dexcom releases on Business Wire. The weekend's press abstracts kept spreading, with gut microbiome and red-meat studies reaching Il Sole 24 Ore, ThePrint and The National. Lilly opened a "House of Lilly" in Milan, drawing skeptical comments from two pharma reporters. None of the morning's industry sessions, including Amgen's symposium (10:00–11:00 BST), appears in media or social coverage in this window.
Escalations: none triggered. The only Amgen mention is an author disclosure in the GLP-1 eligibility study's release ("BGN reports consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Novartis, Novo Nordisk…", FirstWord Pharma, 07:54). No ★ session has taken place yet.
Amgen symposium: "A Patient-Centered Approach to Long-Term Obesity Management" ran 10:00–11:00 BST in Warsaw Hall. No article or public post in this window refers to it, or to the other morning industry sessions by name (Novo's full-day program, Lilly's Industry Day, Roche Pharma Day). Pulsar keeps indexing after publication, so later posts may still appear in the 8am report.
Competitor notes: an investor post says Wegovy tablets now appear on Denmark's medicines price list with pricing effective today (DKK 2,838–3,877 for 30 tablets; @janthecurious1, not verified). Lilly's CEO reshared the "House of Lilly" launch.
Ranked by relevance to obesity and cardiometabolic care, not by volume. Today is industry day; the scientific program starts tomorrow.
An Adnkronos Salute item quoting Abbott ("the evidence supporting continuous glucose monitoring is increasingly solid… ensuring more equitable and uniform access") was syndicated 159 times, led by La Gazzetta del Mezzogiorno (09:37). It links Abbott's Truveta study (44% lower one-year mortality with CGM on basal insulin) to uneven regional reimbursement in Italy. Tandem launched its Mobi automated insulin delivery system in 12 markets "MILAN, September 28" (Yahoo Finance, 37 items), and Dexcom's State of Type 2 report and Team Novo Nordisk partnership reached Morningstar (30 items).
ANSA (reach 1.7M) quotes Prof. Buscemi of the Italian Obesity Society (SIO): reimbursing the new drugs for half a million high-risk Italians with obesity would "cost much less" than a recent car-tax measure, with possible savings of €1.6 billion (ANSA, 10:52). Sanità33 notes that SID/AMD guidelines recommend CGM on basal insulin alone but reimbursement still differs by region. ANSA's opening story leads with Novo's free screening at CityLife and the public 5K on Thursday (Gazzetta di Mantova, 13:56).
@EliLillyandCo (146k): "In Milan, Italy, we're opening House of Lilly during #EASD2026. It brings art and science together…" Lilly CEO Dave Ricks reshared it. Within the hour, reporter Michelle Fay Cortez quote-posted "Health is our highest artform?… This is baffling" (X), and Kyle LaHucik asked "does this mean Gaga will become the next Lilly celebrity spokesperson? @DaveARicks" (X). The posts they quote are not in the data. Lilly's regional accounts promoted "150 years of medicine", the IDF mobile screening unit and a session recording on visceral fat.
Il Sole 24 Ore (1.3M) paired the microbiome signature (789 bacterial species, 229,000 adults) with the red-meat Neu5Gc study (63% higher T2D risk); ThePrint (568k, plus a post to its 505k X followers) and The National (UAE) followed. The Telegraph's "four million more" GLP-1 story was syndicated on MSN (13:34), and the Danish cancer study reached 14 more US radio bulletins and Medical Republic (AU).
What it means for Amgen. Amgen's symposium took place this morning, but no media or public social coverage of it appears in this window; the only Amgen mention is a conflict-of-interest line. Clinicians are already live-posting from obesity sessions (e.g. Prof. Wasim Hanif on SURMOUNT-MAINTAIN, and a dedoc° advocate on amylin and glucagon), so session content can travel on social before press picks it up. Amgen's next scheduled items are MariTide abstract 121 in OP 21 (Wed 13:30 BST) and abstract 1272 (Thu 11:45 BST). On the AI side, Gemini names abstract 121, ChatGPT now finds the symposium but no MariTide abstract, and Claude has reverted to saying it found no Amgen announcement (section 07).
Sources: Amgen competitor planner (4 Sep); EASD final programme; company and society posts. Changes since 8am: the EU Screening Week press conference time comes from the European Diabetes Forum (listed as 15:45–16:20, taken as CEST), which puts it after the Tuesday 3pm cut-off. EASD's post today gives 09:00 CEST for its opening highlights; the programme lists the Presidential Address at 08:30 CEST. Lilly's Industry Day and Amgen's symposium have taken place.
What is driving the conversation, and who is most vocal and what they are saying that is contributing to the congress.
Items = articles, syndicated copies, broadcast mentions and social posts incl. reshares, each counted once. About 85 further items are delegate posts, general previews and off-topic content.
| Narrative | Lead item | BST |
|---|---|---|
| Abbott | Adnkronos via La Gazzetta del Mezzogiorno: "conferme per monitoraggio continuo glucosio ma accesso disomogeneo" | 09:37 |
| Tandem | Yahoo Finance (16.6M): Tandem Mobi in 12 markets | 08:00 |
| Dexcom | Morningstar (2.4M): State of Type 2 report | 07:21 |
| Press abstracts | Il Sole 24 Ore (1.3M): "due nuovi indizi per anticiparlo" | 07:46 |
| Cancer study | Medical Republic (AU): "Cancer gap widens in type 2 diabetes" | 13:07 |
| Lilly | @EliLillyandCo: "we're opening House of Lilly" | 13:00 |
| dedoc° | @CaroGoLoop: "Wer braucht GLP1? Und welche Effekte hat Amylin dabei?" | 11:35 |
| Novo | @peter_torngren: "Novo brings 44 abstracts to Milan" | 08:44 |
| T1D therapies | NextCell (Cision): INNODIA presentation; no ProTrans-Young results yet | 08:15 |
| # | Voice | Type | Posts | Reshared | Audience | What they're saying |
|---|---|---|---|---|---|---|
| 1 | @CaroGoLoop CaroGo, person with T1D | Patient advocate · DE | 8 | – | 488 | The most active account: live German notes from an amylin and incretin session, e.g. "Amylin and GLP-1 act at similar sites in the brain" and "Cagrilintide plus retatrutide combined give massive effects on eating behavior and weight". Attends as a dedoc° voice. |
| 2 | @EASDnews | Society | 3 | 5 | 13.8k | "Doors are open! #EASD2026 is officially underway in Milan & industry sessions are underway." Also the Welcome Reception (16:00 BST) and tomorrow's Presidential Address and Claude Bernard Lecture. |
| 3 | @EliLillyandCo · @LillyDiabetesIn · @LillyObesityInt | Company | 3 | 9 | 146k · 2.8k | House of Lilly ("art and science together"), reshared by CEO Dave Ricks; "150 years of medicine"; free screening via IDF Europe's mobile unit; a session recording on visceral fat. Several reshares come from crypto-spam accounts. |
| 4 | @ConscienHealth Ted Kyle | Obesity policy blogger | 3 | 4 | 11.5k | "We're expecting a flood of news… new clinical guidance on diabetes care that gives attention to obesity." Blog: "A Blockbuster Obesity and Diabetes Meeting in Milan". The most-engaged X post of the window (4). Also reshared Miriam Tucker's preview. |
| 5 | @NovoNordiskLive | Company | 0 | 5 | 16.1k | Reshared posts only: CongressHub, "native amylin", and the 5K@EASD group run "Thursday, 1 October at 7 AM" (06:00 BST). |
| 6 | @docwas Prof. Wasim Hanif OBE | Clinician | 4 | – | 5.2k | Live from obesity sessions: "SURMOUNT-MAINTAIN answers the important question of 'What happens when you stop a Mounjaro?'… if you stop completely you will gain weight"; obesity and sarcopenia in South Asian people; psychological barriers ("the 5 As"). |
| 7 | @AskDrShashank Dr Shashank Joshi | Clinician · IN | 4 | 2 | 33.4k | Speaking at 08:00 BST in Oslo Hall (EASD e-learning): "Disease Modifying therapies from Glucose Control to Metabolic Prevention". Two of his posts are self-reshares. |
| 8 | @peter_torngren | Investor | 4 | – | 974 | A $NVO thread: "The key question is no longer whether Novo has a pipeline… EASD could help reset that narrative." 3 engagements. |
| 9 | @MiriamETucker | Journalist | 1 | 1 | 10.4k | "Here's a preview of #EASD2026". She is the reporter Claude and Gemini both name as the most consistent at this meeting (section 07). |
| 10 | @umdiabetico Tom Bueno | Patient creator · BR | 1 | – | 242k | The most-engaged post (11): "Eu e a Dra. Denise Franco acompanhamos simpósios e palestras da indústria farmacêutica" (covering industry symposia); asks followers what to investigate. |
Indigo edge = company-owned or company-sponsored. Largest audiences this window are news brands and HCP creators: ThePrint (505k, red meat), Turkish endocrinologist Prof. Fevzi Balkan (314k, UPF study) and Saudi physician Dr Hassan Almogbel (26.6k, attending). Flagged, not counted as influence: reshares of Lilly posts from crypto-promotion accounts (names with "Gate", "Bitget", "BG"), and a "$CHONK x $LLY" meme-coin reply.
Why each theme matters for obesity, type 2 diabetes or cardiometabolic care.
| Theme | Area | Why it matters | Evidence | Status |
|---|---|---|---|---|
| Reimbursement of obesity drugs SIO in ANSA | Policy · IT | An Italian society argues reimbursement for 500,000 high-risk patients would pay for itself (€1.6bn savings), timed to the host congress. | Society cost estimate | EmergingHigh stakes |
| GLP-1 eligibility below the obesity threshold News-Medical; Telegraph via MSN | Care · policy | Second-day pickup of the BMI 25–26.9 study, with the authors' caveat that "clinical trials are now needed". | Observational, n = 313,145 | Emerging |
| What happens after stopping SURMOUNT-MAINTAIN via @docwas | Care | Weight regain after stopping tirzepatide is being discussed on day one, which points to maintenance dosing and long-term therapy as a talking point. | RCT (company-sponsored), as relayed by a clinician | EstablishedGrowing |
| Amylin and multi-agonist combinations dedoc° live notes; Virus.com.gr (GR) | Science | "Are we entering the era of combination therapies?" (Greek pharmacists' association). Amylin is the recurring mechanism in session notes ahead of Wednesday. | Session commentary; phase 2–3 data pending | Emerging |
| CGM in type 2 diabetes Abbott; Dexcom; Doctor33 | Care · technology | Mortality association (1.16% vs 2.09% at 12 months) plus access arguments; CGM is positioned alongside GLP-1 therapy in company messaging. | Target-trial emulation (Abbott researchers); company surveys | EstablishedCompany-driven |
| Early detection Microbiome, red meat (Il Sole 24 Ore) | Science | Risk signals before glucose rises. One commentator questions the practical value against CGM. | Observational cohorts | Emerging |
Left edge: red = highest relevance to the incretin class, amber = moderate, teal = contextual.
Obesity and related-condition coverage: who published it, outlet tier and reach, journalist and topic.
| Outlet | Tier | Journalist | Topic | BST | Reach |
|---|---|---|---|---|---|
| ANSA IT | Tier 1 | – | SIO: reimbursing obesity drugs could save €1.6bn | 10:52 | 1.7M |
| Il Sole 24 Ore IT | Tier 1 | Francesca Cerati | Gut microbiome and red meat: "two new clues" to anticipate T2D | 07:46 | 1.3M |
| Yahoo Finance US · Business Wire | Tier 1 · priority | – | Tandem Mobi now in 12 international markets | 08:00 | 16.6M |
| The Telegraph via MSN UK | Tier 1 | Michael Searles | "Give four million more people weight-loss drugs for heart health" | 13:34 | 37M* |
| Adnkronos Salute IT · 159 copies | Tier 2 · wire | – | Abbott: CGM evidence solid, access uneven across regions | 09:37 | 123k (lead) |
| Morningstar US · 26 copies | Tier 2 | – | Dexcom State of Type 2 report | 07:21 | 2.4M |
| ThePrint IN | Tier 2 | Purvi Rajpuria | Red-meat sugar Neu5Gc and 63% higher T2D risk | 12:21 | 568k |
| DiLei IT | Tier 2 | Federico Mereta | Congress opener: prevention, devices, T1D cell therapy (SID's Buzzetti) | 13:56 | 515k |
| News-Medical UK · 4 EASD stories | Tier 2 | – | GLP-1 eligibility, CGM mortality, orforglipron, red meat | 09:42–09:48 | 374k |
| The National UAE | Tier 2 | Paul Carey | "Hopes for early diabetes diagnosis after link found with gut bacteria" | 10:56 | 289k |
| Naver KR | Aggregator | – | EASD's diabetes-distress guideline (republished) | 09:51 | 19M* |
| Medical Republic AU | Tier 3 | Amanda Sheppeard | "Cancer gap widens in type 2 diabetes" | 13:07 | 13k |
| US radio iHeart/Premiere health update · 14 bulletins | Broadcast | Scott Pringle | Danish T2D–cancer study | from 08:50 | ≤65k/station |
Tier 1 = national news or major financial/medical outlet; Tier 2 = large regional, national-language or specialist; Tier 3 = niche. Reach is Pulsar's outlet-level estimate (*portal-wide figures). Public reporter comments: Michelle Fay Cortez and Kyle LaHucik on X, both reacting to Lilly (section 01); reporters' outlets are not recorded in the data.
Clinicians, researchers, advocates, societies and independent creators: role, topic, original post or quoted article, and evidence of amplification.
| Who | Role | Topic & original | Amplification | Disclosed ties |
|---|---|---|---|---|
| Prof. Wasim Hanif OBE | Diabetologist (UK) | SURMOUNT-MAINTAIN, obesity in South Asian populations, barriers to obesity care. X | 5.2k followers; 4 posts | None evident |
| Prof. Buscemi | Italian Obesity Society (SIO) | Reimbursement of new obesity drugs "costerebbe molto meno" than the car-tax measure. ANSA | ANSA 1.7M | None evident |
| Dr Shashank Joshi | Endocrinologist (IN) | "Disease Modifying therapies from Glucose Control to Metabolic Prevention", EASD e-learning session. X | 33.4k followers | None evident |
| Ted Kyle | ConscienHealth (obesity policy) | "A Blockbuster Obesity and Diabetes Meeting in Milan". Instagram | 11.5k on X; reshared by EASO | None disclosed in post |
| Prof. John Petrie | Diabetologist (UK), EGIR | Co-chairing a session in honor of former EASD President Ele Ferrannini, Tue 11:30 BST, Oslo Hall. X | 942 followers | None evident |
| Dr Sónia Gonçalves | Clinician (PT) | Selected for an "eHealth Advisory Board" on digital health in obesity management. Instagram | 2.5k followers | Disclosed advisory board (sponsor not named) |
| CaroGo | Person with T1D, dedoc° voice | Live session notes on amylin, glucagon and GIP. X | 8 posts | Disclosed attends via dedoc° (post of Fri 25 Sep) |
| Tom Bueno & Dr Denise Franco | Patient creator and endocrinologist (BR) | Covering industry symposia from Milan. Instagram | 242k followers | None disclosed |
| Nat (@1derfultype) | Advocate, dedoc° voice | Thread from the INNODIA T1D therapies symposium: "The stakeholders speak different languages". X | 906 followers | Disclosed dedoc° Voices scholarship |
Company voices this window: Lilly CEO Dave Ricks (a reshare of House of Lilly); Novo's CMO Filip Krag Knop in reshared Novo content (8am report). No named speaker from Amgen's symposium posted publicly in this window.
Original posts, reshares and press releases; main claims and themes; comparison with Amgen.
No mentions: AbbVie, Regeneron, Pfizer/Metsera, Viking. Device companies are outside this company list: Abbott about 164 items, Tandem 37, Dexcom 30.
Windows: Fri 25 Sep 03:30–15:30, Fri 15:30 – Mon 07:15, and this window. AstraZeneca 3, Regeneron 2, AbbVie, Pfizer/Metsera and Viking 1 each.
| Novo Nordisk | Mostly carried by others: Dexcom's Team Novo Nordisk partnership (26 items), ANSA's opening story on Novo's free screening and public 5K, and investor posts ahead of 44 abstracts ("EASD is a chance to focus on what it still owns: a huge obesity franchise, oral leadership, amylin science", @peter_torngren). Its own accounts posted day four of 5K@EASD and reshared CongressHub content. |
| Eli Lilly | Brand and heritage: House of Lilly ("art and science"), "150 years of innovation in medicine", free screening. Trader alert: "Eli Lilly is on watch this morning" for its industry symposium (@ttvresearch). Retail analysts keep TRIUMPH-2 at "grade B until the slides are public" (@PeptideBriefs). |
| Abbott · Tandem · Dexcom | CGM "evidence increasingly solid" and a call for equitable access (Abbott); Mobi launch in 12 markets (Tandem); CGM plus GLP-1 "convergence" (Dexcom). |
| Others | Zealand/Roche's petrelintide ("up to 10.7% at 42 weeks") and Novo's zenagamtide heading to phase 3, in a Greek overview of combination therapies (Virus.com.gr). T1D companies (NextCell, SAB BIO) at INNODIA. |
Comparison with Amgen. Amgen has no owned or earned EASD content in this window. Lilly and Novo reach the conversation through owned channels (House of Lilly, 5K@EASD, CongressHub) and third parties (Dexcom's partnership, ANSA, investors); device makers use wire releases. Amgen's program continues Wednesday (abstract 121) and Thursday (abstract 1272). Engagement counts are low across the board (most posts 0–3) because counts refresh after collection.
Point-in-time runs at 14:16 BST today (all three), compared with this morning's runs at 07:13–07:20. These are not window counts. Gemini with Google Search is the closest available stand-in for Google's AI answers, not a copy of AI Overviews.
The answer on Amgen now depends on which assistant you ask and when. ChatGPT now confirms Amgen's symposium ("Amgen is participating… 11:00 to 12:00 CEST in the Warsaw Hall") but says the program does "not list MariTide-related abstracts", which is wrong: abstract 121 names maridebart cafraglutide. Claude has gone back to Friday's answer: "I found no announcement that Amgen is presenting MariTide data at EASD 2026", and "Amgen does not appear" in congress listings. Gemini is correct for the third run in a row, and the only assistant to cite abstract 121. None mentions abstract 1272.
| Question | ChatGPT | Claude | Gemini |
|---|---|---|---|
| Is Amgen presenting at EASD? | Symposium yes; "no MariTide abstracts" Partly correct · improved since 07:13 | "No announcement"; not in listings Wrong · reverted since 07:13 | Yes: abstract 121 + symposium Correct (verified) · unchanged |
| Obesity / GLP-1 data? | Novo first, then Lilly | Lilly's retatrutide first, then survodutide; amylin "the emerging second pillar" | Lilly first, then Novo, BI/Zealand, Regeneron |
| Leading companies? | Lilly first (was Novo at 07:13), then Novo, AZ/BI/Roche, Dexcom | Lilly ("the loudest voice this year"), Novo ("the amylin bet"), BI/Zealand | Lilly, Novo, then Abbott and Dexcom |
| What to watch? | T2D consensus first | Guidance documents first | Incretin and obesity drugs first |
| Top voices? | Giorgino, Vilsbøll, Mathieu and Williams plus the speakers of Novo's Monday program (incl. le Roux) | Blüher, Giorgino; Miriam E. Tucker "the single most influential journalist" | Giorgino, Buse and Davies, others |
| Source | ChatGPT | Claude | Gemini | Type |
|---|---|---|---|---|
| Novo Nordisk ScienceHub, release + copies | 5 | 11 | 10 | Competitor |
| EASD easd.org, programme, industry site | 2 | 15 | 5 | Congress |
| Eli Lilly release + copies, lilly.com | 2 | 9 | 5 | Competitor |
| Medscape congress previews | 0 | 8 | 0 | Media |
| Amgen IR, amgen.com, coverage of Amgen | 1 | 6 | 1 | Owned |
| Social & video LinkedIn, Facebook, YouTube | 2 | 1 | 6 | Social |
| Roche medical pages | 0 | 2 | 0 | Company |
| Other media, societies, aggregators incl. device companies | 13 | 10 | 29 | Mixed |
Totals: ChatGPT 25 (22 resolve), Claude 62 (61), Gemini 56 (49). This morning: 26, 53 and 66. Novo and Lilly together account for 7 of ChatGPT's citations, 20 of Claude's and 15 of Gemini's.
Answers about Amgen are unstable. In a single day, Claude went from "no" (Friday) to "yes, a symposium" (07:13) and back to "no announcement" (14:16). ChatGPT went from "no evidence" to "participating". Each assistant searches again every time, and whether it finds the easd-industry.com listing or the programme PDF decides the answer. None of them has yet found an Amgen-owned EASD source to cite; Claude points users to "Amgen's investor newsroom".
Claude now reads financial coverage for Amgen. Its Amgen sources this afternoon include Seeking Alpha, Yahoo Finance, BioSpace and TIKR pieces on MariTide and Amgen's stock, alongside Amgen's IR pages. Its answer centers on MARITIME timing and a switch study rather than on EASD.
Gemini overstates. It is correct on the facts but says Amgen's presence is "heavily featured in the conference's broader discussions". Our data shows no media or social coverage of Amgen at EASD so far. Three of its six Amgen citations are unrelated pages (a lung-cancer article, a Facebook post, a marketplace page).
Statements quoted are the assistants' own. We verified the Amgen programme items against EASD's final programme; other claims are not verified.
The same question put to three assistants, with verbatim excerpts, run times and the sources each one cited.